(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -8.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Arrowhead Pharmaceuticals's revenue in 2026 is $669,495,000.On average, 16 Wall Street analysts forecast ARWR's revenue for 2026 to be $65,821,756,533, with the lowest ARWR revenue forecast at $51,218,869,734, and the highest ARWR revenue forecast at $94,923,001,824. On average, 15 Wall Street analysts forecast ARWR's revenue for 2027 to be $44,163,209,108, with the lowest ARWR revenue forecast at $15,809,199,947, and the highest ARWR revenue forecast at $74,929,844,565.
In 2028, ARWR is forecast to generate $86,865,847,026 in revenue, with the lowest revenue forecast at $44,297,400,851 and the highest revenue forecast at $153,543,605,629.